Brief: Abbvie Says Risankizumab In Ulcerative Colitis Shows Clinical Remission Rates Of 54.0%-73.1% At Week 96
17/10/2026 07:05
BRIEF-Abbvie Says Risankizumab In Ulcerative Colitis Shows Clinical Remission Rates Of 54.0%-73.1% At Week 96 Oct 17 (Reuters) - AbbVie Inc. ABBV.N:
ABBVIE - RISANKIZUMAB IN ULCERATIVE COLITIS SHOWS CLINICAL REMISSION RATES OF 54.0%-73.1% AT WEEK 96
ABBVIE - UPADACITINIB IN CROHN'S DISEASE SHOWS CLINICAL REMISSION RATES OF 78.9%-86.6% AT WEEK 144
Source text: ID:nPn2bFQWra
Further company coverage: ABBV.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AbbVie
See all newsBrief: Abbvie Reaches Agreement With The Pan-Canadian Pharmaceutical Alliance (Pcpa) For Elahere® In Platinum-Resistant Ovarian Cancer
Eli Lilly hits record high as healthcare stocks rally
Nvidia-backed Iambic Therapeutics tumbles below IPO price
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Brief: Abbvie Says Risankizumab In Ulcerative Colitis Shows Clinical Remission Rates Of 54.0%-73.1% At Week 96